share_log

AbbVie | 8-K: AbbVie Reports Third-Quarter 2024 Financial Results

AbbVie | 8-K: AbbVie Reports Third-Quarter 2024 Financial Results

艾伯维公司 | 8-K：艾伯维公布2024年第三季度财务业绩
美股SEC公告 ·  2024/10/30 19:47

Moomoo AI 已提取核心信息

AbbVie reported Q3 2024 revenues of $14.46 billion, up 3.8% year-over-year, driven by strong performance across key portfolios. Immunology revenues grew 3.9% to $7.05 billion, with Skyrizi and Rinvoq showing robust growth of 50.8% and 45.3% respectively, offsetting Humira's 37.2% decline. Neuroscience revenues increased 15.6% to $2.36 billion, led by Vraylar and Botox Therapeutic.The company raised its full-year 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87, reflecting strong business momentum. Additionally, AbbVie announced a 5.8% increase in quarterly dividend to $1.64 per share, marking its 310% dividend growth since 2013.AbbVie completed the acquisition of Cerevel Therapeutics, strengthening its neuroscience portfolio with complementary pipeline assets. The company also reported positive Phase 3 results for tavapadon in early Parkinson's disease and received FDA approval for Vyalev as the first subcutaneous 24-hour levodopa-based therapy for advanced Parkinson's disease.
AbbVie reported Q3 2024 revenues of $14.46 billion, up 3.8% year-over-year, driven by strong performance across key portfolios. Immunology revenues grew 3.9% to $7.05 billion, with Skyrizi and Rinvoq showing robust growth of 50.8% and 45.3% respectively, offsetting Humira's 37.2% decline. Neuroscience revenues increased 15.6% to $2.36 billion, led by Vraylar and Botox Therapeutic.The company raised its full-year 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87, reflecting strong business momentum. Additionally, AbbVie announced a 5.8% increase in quarterly dividend to $1.64 per share, marking its 310% dividend growth since 2013.AbbVie completed the acquisition of Cerevel Therapeutics, strengthening its neuroscience portfolio with complementary pipeline assets. The company also reported positive Phase 3 results for tavapadon in early Parkinson's disease and received FDA approval for Vyalev as the first subcutaneous 24-hour levodopa-based therapy for advanced Parkinson's disease.
艾伯维公司报告2024年第三季度收入为144.6亿美元，同比增长3.8%，得益于核心产品组合的强劲表现。免疫学收入增长3.9%，达到70.5亿美元，其中Skyrizi和Rinvoq分别显示出50.8%和45.3%的强劲增长，抵消了Humira 37.2%的下降。神经科学收入增长15.6%，达到23.6亿美元，由Vraylar和Botox治疗推动。该公司将2024年全年调整后每股收益指引提高至10.90美元至10.94美元，低于之前的10.67美元至10.87美元，反映出强劲的业务势头。此外，艾伯维公司宣布季度股息增加5.8%，达到每股1.64美元，自2013年以来增长310%。艾伯维公司完成了...展开全部
艾伯维公司报告2024年第三季度收入为144.6亿美元，同比增长3.8%，得益于核心产品组合的强劲表现。免疫学收入增长3.9%，达到70.5亿美元，其中Skyrizi和Rinvoq分别显示出50.8%和45.3%的强劲增长，抵消了Humira 37.2%的下降。神经科学收入增长15.6%，达到23.6亿美元，由Vraylar和Botox治疗推动。该公司将2024年全年调整后每股收益指引提高至10.90美元至10.94美元，低于之前的10.67美元至10.87美元，反映出强劲的业务势头。此外，艾伯维公司宣布季度股息增加5.8%，达到每股1.64美元，自2013年以来增长310%。艾伯维公司完成了对Cerevel Therapeutics的收购，加强了其神经科学产品组合，拥有互补的管线资产。该公司还报告了tavapadon在早期帕金森病的三期临床试验的积极结果，并获得FDA批准，Vyalev成为首个用于晚期帕金森病的24小时皮下给药基于左旋多巴的治疗。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间